FrancophonIA/ELRC3.0 huggingface dataset:
English: Figure 2 ACR20 response in PsA study 2 over time up to week 52
Croatian: Slika 2 Odgovor ACR20 u 2. ispitivanju PsA tijekom vremena do 52. tjedna
English: Patients with each subtype of PsA were enrolled in these studies, including polyarticular arthritis with no evidence of rheumatoid nodules, spondylitis with peripheral arthritis, asymmetric peripheral arthritis, distal interphalangeal involvement and arthritis mutilans.
Croatian: U ova ispitivanja bili su uključeni bolesnici sa svim podtipovima PsA, uključujući i s poliartikularnim artritisom bez dokaza reumatoidnih kvržica, spondilitisom s perifernim artritisom, asimetričnim perifernim artritisom, zahvaćenošću distalnih interfalangealnih zglobova i artritisom mutilansom.
English: The mean volume of distribution during the terminal phase (Vz) following single intravenous administration ranged from 7.10 to 8.60 litres in plaque psoriasis patients, suggesting that secukinumab undergoes limited distribution to peripheral compartments.
Croatian: Srednji volumen distribucije tijekom terminalne faze (Vz) nakon jednokratne intravenske primjene bio je u rasponu od 7,10 do 8,60 litara u bolesnika s plak psorijazom, što ukazuje na to da sekukinumab prolazi ograničenu distribuciju u periferne odjeljke.
English: Serious infections were reported in 1.2% of patients treated with secukinumab (0.015 per patient-year of follow-up).
Croatian: Ozbiljne infekcije bile su zabilježene u 1,2% bolesnika liječenih sekukinumabom (0,015 po bolesnik-godini naknadnog praćenja).
English: ASDAS-CRP major improvement * p<0.05, ** p<0.01, *** p<0.001; versus placebo All p-values adjusted for multiplicity of testing based on pre-defined hierarchy, except BASDAI 50 and ASDAS-CRP
Croatian: ASDAS-CRP veliko poboljšanje * p<0,05, ** p<0,01, *** p<0,001; u odnosu na placebo Sve p-vrijednosti prilagođene za višestrukost testiranja na temelju unaprijed definirane hijerarhije, osim BASDAI 50 i ASDAS-CRP
English: Serum levels of total IL-17A (free and secukinumab-bound IL-17A) are initially increased in patients receiving secukinumab.
Croatian: Razine ukupnog IL-17A (slobodnog IL-17A i onog vezanog za sekukinumab) u serumu u početku su povećane u bolesnika koji primaju sekukinumab.
English: Population pharmacokinetic analysis suggests that steady-state is reached after 20 weeks with monthly dosing regimens.
Croatian: Populacijska farmakokinetička analiza ukazuje na to da se stanje dinamičke ravnoteže postiže nakon 20 tjedana uz mjesečne režime doziranja.
English: Caution should be exercised when prescribing secukinumab to patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
Croatian: Potreban je oprez pri propisivanju sekukinumaba bolesnicima s upalnom bolešću crijeva, uključujući Chronovu bolest i ulcerozni kolitis.
English: This is followed by a slow decrease due to reduced clearance of secukinumab-bound IL-17A, indicating that secukinumab selectively captures free IL-17A, which plays a key role in the pathogenesis of plaque psoriasis.
Croatian: Nakon toga slijedi polagano smanjivanje zbog smanjenog klirensa IL-17A vezanog za sekukinumab, što ukazuje na to da sekukinumab selektivno hvata slobodni IL-17A, koji igra ključnu ulogu u patogenezi plak psorijaze.
English: Do not shake or invert the vial.
Croatian: Nemojte tresti ili preokretati bočicu.
English: No pharmacokinetic data are available in patients with renal or hepatic impairment.
Croatian: Nema dostupnih farmakokinetičkih podataka u bolesnika s oštećenjem bubrega ili jetre.
English: Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes.
Croatian: Sekukinumab djeluje tako da se usmjerava na IL-17A i inhibira njegovu interakciju s IL-17 receptorom, koji je prisutan na raznim vrstama stanica, uključujući keratinocite.
English: Larger differences in response rates, favouring 300 mg over 150 mg, were observed in anti-TNFα-IR patients (n=36) compared to anti-TNFα-naïve patients (n=114).
Croatian: Veće razlike u stopama odgovora, u korist 300 mg u odnosu na 150 mg, bile su opažene u anti-TNFα-NO bolesnika (n=36) u usporedbi s bolesnicima koji nisu ranije primali anti-TNFα (n=114).
English: The box contains Cosentyx pre-filled syringe(s) individually sealed in a plastic blister.
Croatian: Kutija sadrži Cosentyx napunjenu(e) štrcaljku(e) pojedinačno zapakiranu(e) u plastičnom blisteru.
English: • It is preferable to avoid the use of Cosentyx in pregnancy.
Croatian: • Preporučuje se izbjegavati primjenu Cosentyxa u trudnoći.
English: Serious infections occurred in 0.14% of patients treated with secukinumab and in 0.3% of patients treated with placebo (see section 4.4).
Croatian: Ozbiljne infekcije pojavile su se u 0,14% bolesnika liječenih sekukinumabom te u 0,3% bolesnika koji su primali placebo (vidjeti dio 4.4).
English: ASAS: Assessment of SpondyloArthritis International Society Criteria; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; hsCRP: high-sensitivity C-reactive protein; ASDAS: Ankylosing Spondylitis Disease Activity Score; BSL: baseline
Croatian: ASAS: kriteriji Međunarodnog društva za procjenu spondiloartritisa; BASDAI: Bath indeks aktivnosti ankilozantnog spondilitisa; hsCRP: C-reaktivni protein visoke osjetljivosti; ASDAS: Rezultat za aktivnost ankilozantnog spondilitisa; PV: početna vrijednost
English: Patients should be instructed to inject the full amount of Cosentyx according to the instructions provided in the package leaflet.
Croatian: Bolesnike je potrebno uputiti da ubrizgaju cjelokupnu količinu Cosentyxa prema uputama navedenima u uputi o lijeku.
English: These instructions are to help you to inject correctly using the Cosentyx SensoReady pen.
Croatian: Svrha ovih uputa je da Vam pomognu pravilno ubrizgati lijek korištenjem Cosentyx SensoReady brizgalice.
English: IGA mod 2011 “clear” or “almost clear” response n (%) * The IGA mod 2011 is a 5-category scale including “0 = clear”, “1 = almost clear”, “2 = mild”, “3 = moderate” or “4 = severe”, indicating the physician's overall assessment of the psoriasis severity focusing on induration, erythema and scaling.
Croatian: Odgovor IGA mod 2011 „čista“ ili „gotovo čista“ n (%) * IGA mod 2011 je ljestvica od 5 kategorija koja uključuje ocjene „0 = čista“, „1 = gotovo čista“, „2 = blaga“, „3 = umjerena“ ili „4 = teška“ te označava liječnikovu cjelokupnu procjenu težine psorijaze s fokusom na zadebljanja, eritem i ljuštenje.
English: • abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs of bowel problems)
Croatian: • grčevi i bol u trbuhu, proljev, gubitak težine ili krv u stolici (znakovi problema s crijevima)
English: Expel the air bubbles and advance the plunger to the 1.0 ml mark.
Croatian: Izbacite mjehuriće zraka i gurnite klip do oznake za 1,0 ml.
English: Population pharmacokinetic analysis showed that secukinumab was absorbed with an average absolute bioavailability of 73% in patients with plaque psoriasis.
Croatian: Populacijska farmakokinetička analiza pokazala je da se sekukinumab apsorbirao uz prosječnu apsolutnu bioraspoloživost od 73% u bolesnika s plak psorijazom.
English: If necessary, Cosentyx may be stored unrefrigerated for a single period of up to 4 days at room temperature, not above 30°C.
Croatian: Ako je potrebno, Cosentyx se može čuvati izvan hladnjaka tijekom jednokratnog razdoblja od najviše 4 dana na sobnoj temperaturi, ne iznad 30 °C.
English: The renal elimination of intact secukinumab, an IgG monoclonal antibody, is expected to be low and of minor importance.
Croatian: Očekuje se da će bubrežna eliminacija nemetaboliziranog sekukinumaba, koji je IgG monoklonsko protutijelo, biti niska i male važnosti.
English: Secukinumab is a recombinant fully human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells.
Croatian: Sekukinumab je rekombinantno potpuno humano monoklonsko protutijelo koje se proizvodi u stanicama jajnika kineskog hrčka (engl.
English: For other psoriatic arthritis patients:
Croatian: Za ostale bolesnike s psorijatičnim artritisom:
English: In psoriasis phase 3 clinical studies, neutropenia was more frequently observed with secukinumab than with placebo, but most cases were mild, transient and reversible.
Croatian: U kliničkim ispitivanjima psorijaze faze 3, neutropenija je učestalije bila uočena uz sekukinumab nego uz placebo, ali slučajevi su većinom bili blagi, prolazni i reverzibilni.
English: Replace the attached needle with a 27G x ½″ needle.
Croatian: Zamijenite pričvršćenu iglu iglom od 27G x ½″.
English: Bring the vial of powder to room temperature and ensure that the sterile water for injections is at room temperature.
Croatian: Pustite da bočica s praškom dosegne sobnu temperaturu i osigurajte da je sterilna voda za injekcije sobne temperature.
English: • This means the medicine has been delivered.
Croatian: • To znači da je lijek ubrizgan.
English: • if you have recently had a vaccination or if you are due to have a vaccination during treatment with Cosentyx.
Croatian: • ako ste nedavno primili cjepivo ili ako biste trebali primiti cjepivo tijekom liječenja
English: • runny nose (rhinorrhoea)
Croatian: • curenje nosa (rinoreja)
English: This needle will only be used for withdrawing Cosentyx into the disposable syringe.
Croatian: Ta će se igla koristiti samo za izvlačenje Cosentyxa u štrcaljku za jednokratnu uporabu.
English: Carefully remove the needle cap from the syringe.
Croatian: Pažljivo maknite poklopac igle sa štrcaljke.
English: In an additional psoriasis study (CLEAR) 676 patients were evaluated.
Croatian: U dodatnom ispitivanju psorijaze (CLEAR) ocjenjivano je 676 bolesnika.
English: IgGs are mainly eliminated via catabolism and hepatic impairment is not expected to influence clearance of secukinumab.
Croatian: IgG-i se uglavnom eliminiraju putem katabolizma te se ne očekuje da će oštećenje jetre utjecati na klirens sekukinumaba.
English: Carefully withdraw slightly more than 1.0 ml of the solution for subcutaneous injection from the vial into a 1 ml graduated disposable syringe using a suitable needle (e.g. 21G x 2″).
Croatian: Pažljivo izvucite nešto više od 1,0 ml otopine za potkožnu injekciju iz bočice u graduiranu štrcaljku od 1 ml za jednokratnu uporabu pomoću odgovarajuće igle (npr. 21G x 2″).
English: What Cosentyx looks like and contents of the pack Cosentyx powder for solution for injection is a white solid powder in a glass vial.
Croatian: Kako Cosentyx izgleda i sadržaj pakiranja Cosentyx prašak za otopinu za injekciju je bijeli čvrsti prašak u staklenoj bočici.
English: in patients treated with secukinumab compared to patients treated with ustekinumab.
Croatian: u bolesnika liječenih sekukinumabom u usporedbi s bolesnicima liječenim ustekinumabom.
English: It is not known whether secukinumab is excreted in human milk.
Croatian: Nije poznato izlučuje li se sekukinumab u majčino mlijeko.
English: After storage at 2°C to 8°C, the solution should be allowed to come to room temperature for approximately 20 minutes before administration.
Croatian: Nakon čuvanja na 2 °C do 8 °C, otopinu treba pustiti da dosegne sobnu temperaturu otprilike 20 minuta prije primjene.
English: Over the entire treatment period (a total of 3,430 patients treated with secukinumab for up to 52 weeks for the majority of patients), infections were reported in 47.5% of patients treated with secukinumab (0.9 per patient-year of follow-up).
Croatian: Tijekom cijelog razdoblja liječenja (ukupno 3430 bolesnika liječenih sekukinumabom do 52 tjedna za većinu bolesnika), infekcije su bile zabilježene u 47,5% bolesnika liječenih sekukinumabom (0,9 po bolesnik-godini naknadnog praćenja).
English: 1 pre-filled SensoReady pen 2 pre-filled SensoReady pens
Croatian: 1 napunjena SensoReady brizgalica 2 napunjene SensoReady brizgalice
English: Immunoglobulins are excreted in human milk and it is not known if secukinumab is absorbed systemically after ingestion.
Croatian: Imunoglobulini se izlučuju u majčino mlijeko, a nije poznato apsorbira li se sekukinumab sistemski nakon gutanja.
English: Greater efficacy of secukinumab compared to ustekinumab for the endpoints PASI 75/90/100 and IGA mod 2011 0 or 1 response (“clear” or “almost clear”) was observed early and continued through to week 52.
Croatian: Veća djelotvornost sekukinumaba u usporedbi s ustekinumabom za ishode PASI 75/90/100 i IGA mod 2011 odgovor 0 ili 1 („čista“ ili „gotovo čista“) je uočena rano i trajala je do 52. tjedna.
English: Using Cosentyx in plaque psoriasis will benefit you by leading to improvements of skin clearance and reducing your symptoms such as scaling, itching and pain.
Croatian: Korištenje Cosentyxa kod plak psorijaze pomoći će Vam tako što će dovesti do poboljšanog čišćenja kože i smanjenja Vaših simptoma kao što su ljuštenje, svrbež i bol.
English: Caution should be exercised when considering concomitant use of other immunosuppressants and secukinumab (see also section 4.5).
Croatian: Potreban je oprez prilikom razmatranja istodobne primjene drugih imunosupresiva i sekukinumaba (vidjeti također dio 4.5).
English: Psoriasis study 1 (ERASURE) evaluated 738 patients.
Croatian: Prvo ispitivanje psorijaze (ERASURE) ocjenjivalo je 738 bolesnika.
English: Nevertheless, the use of Cosentyx pre-filled pens in latex-sensitive individuals has not been studied and there is therefore a potential risk for hypersensitivity reactions which cannot be completely ruled out.
Croatian: Međutim, primjena Cosentyx napunjenih brizgalica u pojedinaca osjetljivih na lateks nije bila ispitivana, pa stoga postoji potencijalni rizik od reakcija preosjetljivosti koji se ne može u potpunosti isključiti.
English: The mean elimination half-life, as estimated from population pharmacokinetic analysis, was 27 days in plaque psoriasis patients, ranging from 18 to 46 days across psoriasis studies with intravenous administration.
Croatian: Srednji poluvijek eliminacije, procijenjen iz populacijske farmakokinetičke analize, bio je 27 dana u bolesnika s plak psorijazom, u rasponu od 18 do 46 dana u ispitivanjima psorijaze s intravenskom primjenom.
English: • severe itching of the skin, with a red rash or raised bumps.
Croatian: • teški svrbež kože, s crvenim osipom ili izdignutim kvržicama.
English: Patients in Ankylosing Spondylitis study 1 (AS study 1) and Ankylosing Spondylitis study 2 (AS study 2) had a diagnosis of AS for a median of 2.7 to 5.8 years.
Croatian: Bolesnici u 1. ispitivanju ankilozantnog spondilitisa (1. ispitivanje AS-a) i 2. ispitivanju ankilozantnog spondilitisa (2. ispitivanje AS-a) imali su dijagnozu AS-a tijekom medijana od 2,7 do 5,8 godina.
English: For storage conditions after reconstitution of the medicinal product, see section 6.3
Croatian: Uvjete čuvanja nakon rekonstitucije lijeka vidjeti u dijelu 6.3.
English: In PsA study 3, inhibition of progression of structural damage was assessed radiographically and expressed by the modified Total Sharp Score (mTSS) and its components, the Erosion Score (ES) and the Joint Space Narrowing Score (JSN).
Croatian: U 3. ispitivanju PsA, inhibicija progresije strukturalnog oštećenja ocijenjena je radiografski i izražena kao promjena u modificiranom ukupnom rezultatu po Sharpu (mTSS) i njegovim komponentama, rezultatu za eroziju (engl.
English: Psoriasis study 5 (SCULPTURE) evaluated 966 patients.
Croatian: Peto ispitivanje psorijaze (SCULPTURE) ocjenjivalo je 966 bolesnika.
English: Do not use this medicine if either the seal on the outer box or the seal of the blister is broken, as it may not be safe for you to use.
Croatian: Nemojte koristiti ovaj lijek ako je kutija odlijepljena ili ako je folija na blisteru potrgana, budući da u tom slučaju štrcaljka možda nije sigurna za uporabu.
English: In a population pharmacokinetic analysis, the mean systemic clearance (CL) was 0.19 l/day in plaque psoriasis patients.
Croatian: U populacijskoj farmakokinetičkoj analizi, srednji sistemski klirens (CL) bio je 0,19 l/dan u bolesnika s plak psorijazom.
English: Statistically significant improvements at week 12 (studies 1-4) from baseline compared to placebo were demonstrated in the DLQI (Dermatology Life Quality Index).
Croatian: Statistički značajna poboljšanja u 12. tjednu (1.-4. ispitivanje) od početka u usporedbi s placebom bila su dokazana u DLQI-ju (Dermatološki indeks kvalitete života, engl.
English: Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A).
Croatian: Sekukinumab je potpuno humano IgG1/κ monoklonsko protutijelo koje se selektivno veže za proinflamatorni citokin interleukin-17A (IL-17A) i neutralizira ga.
English: The 300 mg dose provided improved skin clearance particularly for “clear” or “almost clear” skin across the efficacy endpoints of PASI 90, PASI 100, and IGA mod 2011 0 or 1 response across all studies with peak effects seen at week 16, therefore this dose is recommended.
Croatian: Doza od 300 mg omogućila je poboljšano čišćenje kože osobito za „čistu“ ili „gotovo čistu“ kožu za mjere ishoda djelotvornosti tj. odgovore PASI 90, PASI 100 i IGA mod 2011 0 ili 1 u svim ispitivanjima, pri čemu su najveći učinci uočeni u 16. tjednu, pa se stoga preporučuje ova doza.
English: Keep the vial standing at room temperature for a minimum of 10 minutes to allow for dissolution.
Croatian: Pustite bočicu na sobnoj temperaturi najmanje 10 minuta kako bi moglo doći do otapanja.
English: An effect of inhibition of structural damage was observed in anti-TNFα-naïve and anti-TNFα-IR patients and in patients treated with and without concomitant MTX.
Croatian: Učinak inhibicije strukturalnog oštećenja bio je opažen u bolesnika koji ranije nisu primali anti-TNFα te u anti-TNFα-NO bolesnika i bolesnika koji su istodobno primali ili nisu primali MTX.
English: Greater response rates favouring 300 mg were also observed for ASAS partial remission (ASAS PR) response at week 16 and were maintained up to week 156.
Croatian: Veće stope odgovora u korist 300 mg bile su opažene i za ASAS odgovor djelomične remisije (ASAS PR) u 16. tjednu te su se održale do 156. tjedna.
English: In a study, after meningococcal and inactivated influenza vaccinations, a similar proportion of healthy volunteers treated with 150 mg of secukinumab and those treated with placebo were able to mount an adequate immune response of at least a 4-fold increase in antibody titres to meningococcal and influenza vaccines.
Croatian: U jednom ispitivanju, nakon primjene cjepiva protiv meningokoka i inaktiviranog cjepiva protiv influence, sličan je udio zdravih dobrovoljaca liječenih sa 150 mg sekukinumaba i onih koji su primali placebo uspio postići odgovarajući imunološki odgovor od najmanje četverostrukog povećanja u titru protutijela na cjepivo protiv meningokoka i influence.
English: Patients were blinded to the treatment regimen up to week 52, and the study continued to week 156.
Croatian: Bolesnici do 52. tjedna nisu znali koji režim liječenja primaju (maskirano razdoblje), a ispitivanje se nastavilo do 156. tjedna.
English: Stop using Cosentyx and tell your doctor or seek medical help immediately if you get any of the following side effects:
Croatian: Prestanite koristiti Cosentyx i odmah se obratite svom liječniku ili potražite liječničku pomoć ako primijetite bilo koju od nuspojava navedenih u nastavku.
English: In PsA study 1, inhibition of structural damage was maintained with secukinumab treatment up to week 52.
Croatian: U 1. ispitivanju PsA, inhibicija strukturalnog oštećenja održala se uz liječenje sekukinumabom do 52. tjedna.
English: Statistically significant improvements in patient-reported signs and symptoms of itching, pain and scaling at week 16 and week 52 (CLEAR) were demonstrated in the Psoriasis Symptom Diary©
Croatian: Statistički značajna poboljšanja u znakovima i simptomima svrbeži, boli i ljuskanja prema izvješćima bolesnika u 16. i 52. tjednu (CLEAR) dokazana su u Dnevniku simptoma psorijaze©
English: Do not use if the safety seal has been broken.
Croatian: Ne upotrebljavajte ako je sigurnosna naljepnica potrgana.
English: The most frequently reported adverse drug reactions (ADRs) are upper respiratory tract infections (most frequently nasopharyngitis, rhinitis).
Croatian: Najučestalije prijavljene nuspojave su infekcije gornjeg dijela dišnog sustava (najčešće nazofaringitis, rinitis).
English: The frequency of IL-17-producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis.
Croatian: Učestalost stanica koje proizvode IL-17 bila je isto tako značajno viša u subhondralnoj koštanoj srži fasetnih zglobova bolesnika s ankilozantnim spondilitisom.
English: • cold sores (oral herpes)
Croatian: • ranice na ustima (oralni herpes)
English: Secukinumab 300 mg met the primary and secondary endpoints by showing superiority to ustekinumab based on PASI 90 response at week 16 (primary endpoint), speed of onset of PASI 75 response at week 4, and long-term PASI 90 response at week 52.
Croatian: Sekukinumab 300 mg je postigao mjere primarnog i sekundarnog ishoda pokazujući superiornost nad ustekinumabom na temelju PASI 90 odgovora u 16. tjednu (mjera primarnog ishoda), brzine pojave PASI 75 odgovora u 4. tjednu i dugoročnog PASI 90 odgovora u 52. tjednu.
English: IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis and is up-regulated in lesional skin in contrast to non-lesional skin of plaque psoriasis patients and in synovial tissue of psoriatic arthritis patients.
Croatian: IL-17A ima ključnu ulogu u patogenezi plak psorijaze, psorijatičnog artritisa i ankilozantnog spondilitisa te mu je razina povećana u koži s lezijama za razliku od kože bez lezija u bolesnika s plak psorijazom i u sinovijalnom tkivu bolesnika s psorijatičnim artritisom.
English: Of the 2,403 patients who were included in the placebo-controlled studies, 79% were biologic-naive, 45% were non-biologic failures and 8% were biologic failures (6% were anti-TNF failures, and 2% were anti-p40 failures).
Croatian: Od 2403 bolesnika koji su bili uključeni u placebom kontrolirana ispitivanja, 79% nije ranije primalo biološke lijekove, u 45% je terapija nebiološkim lijekovima bila neuspješna, a u 8% je terapija biološkim lijekovima bila neuspješna (u 6% je terapija anti-TNF-om bila neuspješna, a u 2% terapija s anti-p40).
English: Most pharmacokinetics properties observed in patients with plaque psoriasis, psoriatic arthritis and ankylosing spondylitis were similar.
Croatian: Većina farmakokinetičkih svojstava uočenih u bolesnika s plak psorijazom, psorijatičnim artritisom i ankilozantnim spondilitisom bila je slična.
English: What you need for your injection:
Croatian: Što Vam treba za injekciju:
English: Do not inject into areas where the skin is tender, bruised, red, scaly or hard.
Croatian: Nemojte ubrizgavati na mjestima na kojima je koža osjetljiva, s modricama, crvena, ljuskasta ili tvrda.
English: Caution should be exercised when considering the use of secukinumab in patients with a chronic infection or a history of recurrent infection.
Croatian: Potreban je oprez kada se razmatra primjena sekukinumaba u bolesnika s kroničnom infekcijom ili rekurentnom infekcijom u anamnezi.
English: Following a single subcutaneous dose of 300 mg as a liquid formulation in healthy volunteers, secukinumab reached peak serum concentrations of 43.2±10.4 μg/ml between 2 and 14 days post dose.
Croatian: Nakon jednokratne supkutane doze od 300 mg u tekućoj formulaciji u zdravih dobrovoljaca, sekukinumab je dosegao vršne koncentracije u serumu od 43,2±10,4 μg/ml između 2. i 14. dana nakon doze.
English: Cosentyx SensoReady pen shown with the cap removed.
Croatian: Cosentyx SensoReady brizgalica prikazana s uklonjenim poklopcem.
English: Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.
Croatian: Cosentyx je indiciran za liječenje aktivnog ankilozantnog spondilitisa u odraslih osoba koje su imale neodgovarajući odgovor na konvencionalno liječenje.